// App-Quantinova.ai

8562 : The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.

Researchers

Presenter

  • Sehhoon Park

Principal Investigators

  • Peter G. Mortimer

  • Simon Smith

  • Heejung (Rosa) Kim

  • Hyun Ae Jung

  • Jong-Mu Sun

  • Jin Seok Ahn

  • Myung-Ju Ahn

  • Woong-Yang Park

  • Se-Hoon Lee

  • Keunchil Park

Medical Centers

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Early Oncology Clinical Science, R&D Oncology, AstraZeneca, Cambridge, United Kingdom

  • External R&D, R&D Oncology, AstraZeneca, Seoul, South Korea

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Samsung Medical Center, Seoul, Korea

  • Samsung Genome Institute, Samsung Medical Center, Seoul, Korea

  • Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea

Locations

  • United Kingdom

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • BRCA mutation

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Olaparib

  • AZD6738

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03009682

  • NCT0328607

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved